Kinney Drugs pulls back AI phone assistant after hundreds of customer complaints

**Kinney Drugs Just Gave Us the Perfect AI Cautionary Tale** Listen up, founders. We love a good AI automation story, but Kinney Drugs just delivered a masterclass in why you don't roll out a half-baked phone bot to a customer base that just wants their prescription refilled. The company pulled its AI phone assistant after "hundreds" of complaints—which is corporate-speak for "thousands of angry seniors yelling at an unfeeling robot." This isn't just a "tech glitch" story. This is a market signal. The AI buzzword bingo era is overasi. Investors are shifting from "How much AI does this product have?" to "Does this AI actually make the customer experience better, or is it just cost-cutting dressed up as innovation?" Kinney tried to route calls through a bot without addressing the *structural* friction. The result? Reputation damage that no LLM prompt can fix. The sharper takeaway for the startup community is about "RPA vs. RPI"—Revenue Protection AI versus Revenue Generating AI. Applied wisely, AI is a growth lever. Applied lazily, it's a churn machine. While enterprise vendors push "AI at every touchpoint," Kinney proves the old school rule still matters: trust with the customer is your only moat. The hospital will be fineaisa, but the velocity of this reversal (days after launch) suggests we're entering an "AI reality-check curve" where bad deployments die fast. **Closer:** Don't automate the chaos if you don't understand the workflow. Otherwise, you're not deploying AI—you're deploying a firing squad for your NPS score. {"key_insight":"Poor AI deployment focused on cost-cutting destroys customer trust faster than it saves money; rollout velocity must prioritize structural fidelity over feature flash.","confidence":0.9}